HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients

Liver International

Volumn 35, Issue s1, 2015, Pages 82-90

  Martinot Peignoux, Michelle ^a   Asselah, Tarik ^a,b   Marcellin, Patrick ^a,b  

^a CENTRE DE RECHERCHE SUR L INFLAMMATION   (France)

^b BEAUJON HOSPITAL   (France)

Author keywords

Analogues; HBV tools; PEG IFN; Personalized medicine; Prediction; Prognosis

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; PEGINTERFERON; BIOLOGICAL MARKERS; DNA, CIRCULAR; DNA, VIRAL; HEPATITIS B SURFACE ANTIGENS; INTERFERON-ALPHA; PEGINTERFERON ALFA-2A; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS;

CLINICAL PRACTICE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; OUTCOME ASSESSMENT; PATIENT MONITORING; PREDICTIVE VALUE; RELAPSE; REVIEW; SYSTEMATIC REVIEW; BLOOD; HEPATITIS B, CHRONIC; HUMANS; IMMUNOASSAY; IMMUNOLOGY; KINETICS; METABOLISM; PROGNOSIS; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; DNA, CIRCULAR; DNA, VIRAL; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOASSAY; INTERFERON-ALPHA; KINETICS; POLYETHYLENE GLYCOLS; PROGNOSIS; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84919683887     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12735     Document Type: Review

References (78)

1. Lok ASF, McMahon BJ. AASLD practice guideline update. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 1-36.
2. Liaw YF, Kao J-H, Piratvisuth T, et al. Asian-Pacific consensus statements on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6: 531-61.
3. EASL. EASL clinical practice guidelines: management of chronic hepatitis B European Association for the Study of the Liver. J Hepatol 2012; 50: 227-42.
4. Chen EQ, Tang H. Optimization therapy for the treatment of chronic hepatitis B. World J Gastroenterol 2014; 21: 5730-6.
5. Marcellin P, Gane RJ, Tsaui N, et al. Seven years of treatment with tenofovir DF for chronic hepatitis B virus infection is safe and well tolerated and associated with sustained virological response with no detectable resistance. Hepatology 2013:58: (Suppl. 4) 649A.
6. Andersson KL, Chung RT. Monitoring during and after therapy for Hepatitis B. Hepatology 2009; 49(Suppl. 5): S166-73.
7. ter Borg MJ, van Zonneveld M, Zeuzem S, et al. Patterns of viral decline during PEG-Interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response. Hepatology 2006; 44: 721-7.
8. Fung J, Lai CL, Tanaka Y, et al. The duration of lamivudine therapy for chronic hepatitis B; cessation vs. continuation of treatment after HBeAg seroconversion. Am J Gastroenterol 2009; 104: 1940-6.
9. Blumberg BS, Alter HJ, Visnich S. . A new antigen in leukemia sera. JAMA 1965; 191: 541-6.
10. Martinot-Peignoux M, Lapalus M, Asselah TAD, Marcellin P. HBsAg quantification: useful for monitoring natural history and treatment outcome. Liver International 2014; 34(Suppl 1): 97-107.
11. Brunetto MR, Moriconi F, Bononi F, et al. Hepatitis B virus surface antigen levels: a guide to sutained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-50.
12. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151-7.
13. Nguyen T, Locarnini S. Monitoring drug therapy for hepatitis B - a global challenge. Nat Rev Gastroenterol Hepatol 2009; 6: 565-7.
14. Gish RG, Locarnini SA. Chronic hepatitis B: current testing strategies. Clin Gastroenterol Hepatol 2006; 4: 666-76.
15. Fried MW, Piratvisuth T, Lau GKK, et al. HBeAg and hepatitis B virus DNA as outcome predictotrs during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008; 47: 428-34.
16. Hansen BE, Buster EHCJ, Steyerberg EW, et al. . Prediction of response to Peg-Inteferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment. J Med Virol 2010; 82: 1135-42.
17. Farci P, Marcellin P, Lu ZM, et al. On-treatment predictors of sustained biochemical and virological response in patients with HBeAg negative chronic hepatitis B treated with pegintrferon alfa-2a. J Hepatol 2005; 42(Suppl. 2): 175.
18. Chang TT. On-treatment monitoring of HBV DNA levels: predicting response and resistance to oral therapy at week 24 versus week 48. Hepatol Int 2009; 3: S16-23.
19. Zeuzem S, Gane E. Liaw YF, et al. Baseline characteristics and early on treatment response predict the outcomes of 2 years of telbuvidine treatment of chronic hepatitis B. J Hepatol 2009; 51: 11-20.
20. Peng CY, Hsieh TC, Hsieh TY, et al. HBV-DNA level at 6 months of entecavir treatment predicts HBe loss in HBeAg positive chronic hepatitis B patients. J Formosan Med Asso. 2013; 112: 1-6.
21. Keefe EB, Zeuzem S, Kokk R, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clinical Gastroenterol Hepatol. 2007; 5: 890-7.
22. Martinot-Peignoux M, Asselah T, Marcellin P. HBsAg quantification to predict natural history and treatment outcome in chronic hepatitis B patients. Clin Liver Dis 2013; 17: 399-412.
23. Chudy M, Scheiblauer H, Hanschman KM, et al. Performance of hepatitis B surface antigen tests with the first WHO international hepatitis B virus genotype reference panel. J Clin Virol 2013; 58: 47-53.
24. Chan HL, Wong VW, Chim AM, et al. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther 2010; 32: 1323-315.
25. Tangkijvanich P, Komolmit P, Mahachai V, et al. Low pretreatment serum HBsAg level and viral mutations as predictors of response to Peginterferon alfa-2b therapy in chronic hepatitis B. J Clin Virol 2009; 46: 117-23.
26. Chen GY, Zhu MF, Zheng DL, et al. Baseline HBsAg predicts response to pegylated interferon alfa 2b in HBeAg positive ccronic hepatitis B patients. World J Gastroenterol 2014; 20: 8195-200.
27. Marcellin P, Curescu MG, Piekarska A, et al. Outcome of treatment with peginterferon alfa 2a (40KD) in HBeAg positive and HBeAg negative patients with chronic hepatitis B (CHB) in the real-world study: interim analysis of data from the large European S-collate cohort. Hepatology 2013;58(Suppl. 4)656A.
28. Piratvisuth T, Marcellin P, Popescu M, et al. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen positive patients. Hepatol Int 2013; 7: 429-36.
29. Su TH, Liu CJ, Yang YM, et al. Clinical significance and evolution of hepatic HBsAg expression in HBeAg positive patients receiving interferon therapy. J Gastroenterol 2014; 49: 356-62.
30. Lau GKK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamuvidine, and the combination for HbeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95.
31. Lau G, Marcellin P, Brunetto M. On treatment monitoring of HBsAg levels to predict response to peginterferon alfa-2a in patients with HBeAg-positive Chronic hepatitis B. J Hepatol 2009; 50: S333.
32. Gane E, Jia J, Han K, et al. NEPTUNE study; on treatment HBs Ag level analysis confirms prediction of response observed in phase 3 study of peginterferon alfa-2a in HBeAg positive patients. J Hepatol 2011;58(4)Suppl: 656A. Abstract 69.
33. Sonneveld MJ, Rijckborst V, Boucher CA, et al. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010; 52: 1251-7.
34. Flink HJ, van Zonneveld M, Hansen B, et al. treatment with Peg-Interferon a-2a for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype? Am J Gastroenterol 2006; 101: 297-303.
35. Soneveld MJ, Rijckborst V, Cakalog Y, et al. Durable hepatitis surface antigen decline in hepatitis B e antigen positive chronic hepatitis B patients treated with pegylated interferon-a2b: relation to response and HBV genotype. Antivir Ther 2012; 17: 9-17.
36. Moucari R, Martinot-Peignoux M, Mackiewicz V, et al. Influence of genotype on hepatitis B surafce antigen in hepatitis B e antigen-negative patients trated with pegylated interferon-alpha-2a. Antivir Ther 2009; 14: 1183-8.
37. Brunetto MR, Marcellin P, Cherubin B, et al. Response to peginterferon alfa-2a(40KD) in HBeAg-negative CHB: on treatment kinetics of HBsAg serum levels vary by HBV genotype. J Hepatol 2013; 59: 1153-9.
38. Sonneveld MJ, Hansen BE, Piratvisuth T, et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis surface antigen levels. Hepatology 2013; 3: 872-80.
39. Hadziyannis SJ. Treatment paradigms on hepatitis Be antigen negative chronic hepatitis B patients. Expert Opin Investig Drigs 2007; 16: 777-86.
40. Rijckborst V, Hansen BE, Cakalog Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010; 52: 454-61.
41. Marcellin P, Bonino F, Yurdayin C, et al. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e antigen-negative patients. Hepatol Int 2013; 7: 88-97.
42. Moucari R. Peginterferon for chronic hepatitis B: predicting success with on-treatment benchmarks. J Gastroenterol Hepatol 2010; 25: 1474-5.
43. Moucari R, Korevaar A, Lada O, et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol 2009; 50: 1084-92.
44. Rijckborst V, Hansen BE, Ferenci P, et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alpha-2a. J Hepatol 2012; 6: 1006-11.
45. Iannazzo S, Coco B, Brunetto MR, et al. Individualized treatment of HbeAg-negative chronic hepatitis B using pegylated interferon -a2a as first line and weel-12 HBVDNA/HBsAg stopping rule; a cost-effectiveness analysis. Antiviral Tharapy 2013; 18: 623-33.
46. Marcellin P, Bonino F, Lau GKK, et al. Sustained response of Hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alfa-2a. Gastroenterology 2009; 136: 2169-79.
47. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17.
48. Reijnders JG, Rijckborst V, Sonneveld MJ, et al. Kinetics of hepatits B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol 2011; 54: 449-54.
49. Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are the most effective antiviral agent for chronic hepatitis B: a systematic review and bayesian meta-analysis. Gastroenterology 2010; 139: 1218-29.
50. Heathcote EJ, Marcellin M, Buti M, et al. Three years efficacy and safety of Tenofovir Disiproxil Fumarate treatment for chronic hepatitis B. Gastroenterrology 2011; 140: 132-43.
51. Wursthorn K, Jung M, Riva A, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010; 52: 1611-20.
52. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-8.
53. Zoutendijk R, Hansen BE, Van Vuuren AJ, et al. Serum HBsAg decline during long-term potent nucleos(t)ideanalogue therapy for chronic hepatitis B and prediction of HBsAg loss. JID 2011; 204: 415-8.
54. Chevaliez S, Hezode C, Baharami S, et al. Long-term hepattitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite duration of treatment unlikely. J Hepatol 2013; 58: 676-83.
55. Lee MH, Lee DM, Kim SS, et al. Correlation of serum hepatitis B srface antigen level with response to entecavir in naive patients with chronic hepatitis B. J Med Virol 2011; 83: 1178-86.
56. Lee JM, Ahn SH, Kim HS, et al. Quantitative hepatitis B surface antigen and hepatitis B e atigen titers in prediction of treatment response to entecavir. Hepatology 2010; 53: 1486-93.
57. Orito E, Fujiwara K, Kanie H, et al. Quantification of HBsAg predicts response to entecavir therapy in HBV genotype C patients. Worl J Gastroenterol 2012; 18: 5570-5.
58. Seto WK, Wong DKH, Fung J, et al. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleotside analogue therapy. Hepatology 2013; 58: 923-31.
59. Wang CC, Tseng TC, Wag PC, et al. Baseline hepatitis B surface antigen quantification can predict virologic response in entecavir treated chronic hepatitis B patients. Journal of Formosan Medical Association 2013; 112: 1-8.
60. Marcellin M, Heathcote EJ, Buti M, et al. Tenofovir Disiproxil Fumarate versus Adefovir Dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-55.
61. Kim SS, Lee D, Lee MH, et al. Association of on-treatment serum hepatitis B surface antigen level with sustained virological response to nucleos(t)ide analog in patients with hepatitis B e-antigen positive chronic hepatitis B. Hepatology Research 2013; 13: 219-27.
62. Gish RG, Chang TT, Lai CL, et al. Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive, nucleoside-naïve patients treated with entecavir. Antiviral Therapt 2013; 18: 691-8.
63. Li MR, Xi HL, Wang QH, et al. Kinetics and prediction of HBsAg loss during long-term therapy with nucleos(ti)de analogues of different potency in patients with chronic hepatitis B. PLOS-one 2014; 9: e98476.
64. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10.
65. Marcellin P, Buti M, Krastev Z, et al. Kinetics of hepatitis B surface antigen loss in patients with HBe-Ag positive chronic hepatitis B treated with tenofovir disoproxil fumarate. J Hepatol 2014; 61: 12228-37.
66. Hosaka T, Suzuki F, Kobayashi M, et al. Clearance of hepatitis B surface antigen during long-term nucleo's)tide analog treatment in chronic hepatitis B patients; results from a nine-year longitudinal study. J Gastroenterol 2013; 48: 930-41.
67. Boglione L, Cardellino CS, de Nicolo A, et al. Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg negative genotpe A, D, and E. J Med Virol 2014; 86: 1845-50.
68. Seto WK, Hui AJ, Wong VWS, et al. Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicenter prospective study. Gut 2014; doi:10.101136/gutjnl-2014-307237.
69. Sohn HR, Min BY, Song JC, et al. Off-treatment vitologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieve complet viral suppression with oral nucleos(t)ides analogs. BMC Infectious Disease 2014; 14: 439-47.
70. He D, Guo S, Chen WC, et al. Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg negative. BMC Infectious Disease 2013; 13: 458-63.
71. Kim YJ, Kim K, Hwang SH, et al. Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients. CMH 2013; 19: 300-4.
72. Patwardhan VR, Sengupa N, Bonder A, et al. Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective follow-ing prolonged anti-viral suppression with nucleosides/nucleotides. AP&T 2014; 40: 804-14.
73. Jeng WJ, Sheen IS, Chen YC, et al. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology 2013; 58: 1888-1896.
74. Reijnders JGP, Perquin MJ, Zhang N, et al. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 2010; 139: 491-8.
75. Chen CH, Lu SN, Hung CH, et al. The role of hepatitis B surface antigen quantification in predicting HBSAg loss and HBv relapse after discontinuation of lamuvidine treatment. J Hepatol 2014; 61: 515-22.
76. Liang Y, Jiang J, Su M, et al. Predictors of relapse in chronic hepatitis B after discontinuation of antiviral therapy. Aliment Pharmacol Ther 2011; 34: 344-52.
77. Chan HLY, Wong GLH, Chim AML, et al. Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative chronic hepatitis B patients? Antivir Ther 2011; 16: 1249-57.
78. Cai W, Xie Q, An B, et al. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. J Clin Virol 2010; 48: 22-6.